Veloxis Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$12.2M
Doctors Paid
2,448
Transactions
9,583
2024 Total
$1.5M
Payment Breakdown by Category
Research$9.0M (73.8%)
Consulting$1.3M (10.8%)
Travel$612,433 (5.0%)
Food & Beverage$369,039 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.0M | 278 | 73.8% |
| Consulting Fee | $1.3M | 492 | 10.8% |
| Travel and Lodging | $612,433 | 1,090 | 5.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $555,528 | 346 | 4.5% |
| Food and Beverage | $369,039 | 6,639 | 3.0% |
| Honoraria | $191,058 | 99 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $82,550 | 37 | 0.7% |
| Education | $63,134 | 598 | 0.5% |
| Grant | $23,500 | 4 | 0.2% |
Payments by Type
Research
$9.0M
278 transactions
General
$3.2M
9,305 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 1, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF VEL-101 ADMINISTERED INTRAVENOUSLY OR SUBCUTANEOUSLY IN HEALTHY SUBJECTS | $1.1M | 0 | 2 |
| AN EFFICACY STUDY WITH VEL-101 ADMINISTERED BY SUBCUTANEOUS INJECTION IN A RHESUS MACAQUE MODEL OF KIDNEY TRANSPLANT | $860,917 | 0 | 3 |
| A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 | $784,213 | 0 | 2 |
| ASSESS SAFETY AND TOLERABILITY OF ART-123 + FOLFOX + BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS | $552,761 | 0 | 80 |
| Assess Safety and Tolerability of ART-123 and FOLFOX Bevacizumab in Metastatic Colorectal Cancer Patients | $366,920 | 0 | 11 |
| Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus | $335,114 | 0 | 5 |
| CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients | $233,172 | 0 | 5 |
| Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant | $191,849 | 0 | 3 |
| Once-daily extended-release tacrolimus vs. twice-daily tacrolimus. Impact on T-cell subpopulations and markers of renal tubule-toxicity in kidney transplant patients | $190,325 | 0 | 3 |
| A Prospective, Randomized, Multicenter, Open-Label, Pilot Study to Investigate Medication Adherence and Patient Reported Symptom Occurrence and Interference with Daily Life Comparing Once-Daily Envarsus XR and Twice-Daily Immediate Release Tacrolimus in Adult Renal Transplant Recipients | $183,600 | 0 | 2 |
| A Prospective Randomized Multicenter OpenLabel Pilot Study to Investigate Medication Adherence and Patient Reported Symptom Occurrence and Interference with Daily Life Comparing OnceDaily Envarsus XR and TwiceDaily Immediate Release Tacrolimus in Adult Renal Transplant Recipients | $183,600 | 0 | 6 |
| Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection | $151,070 | 0 | 7 |
| Envarsus Neurotoxicity Burden in Liver Transplant Patients | $146,786 | 0 | 3 |
| Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients | $137,795 | 0 | 3 |
| Impact of Envarsus XR (r) on kidney biopsy subclinical rejection and blood immunologic profile | $133,302 | 0 | 4 |
| A Phase IV, Prospective, Randomized, Open-label, Single-Center Study of Pulse Wave Velocity Evaluation, Tacrolimus Time in Therapeutic Range and Co-Efficient fo Tacrolimus Variation of African American Kidney Transplant Recipients Receiving Immediate Release Tacrolimus Capsules (IR-Tac) or Extended Release | $133,229 | 0 | 1 |
| Phase II, single-center, Open-label study to evaluate the comparable efficacy of Tacrolimus extended release tablets Envarsus r to the standard of care SOC twice daily tacrolimus Prograf r dosing regimen | $131,512 | 0 | 3 |
| COGNITIVE OUTCOMES IN STABLE RENAL TRANSPLANT PATIENTS SWITCHED FROMTACROLIMUS TO ENVARSUS XR (OPERATOR) | $123,275 | 0 | 2 |
| Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PTAAK) | $122,354 | 0 | 2 |
| ASSESSMENT OF MEDICATION ADHERENCE AMONG KIDNEY, PANCREAS, AND LIVER TRANSPLANT RECIPIENTS WITH VARYING DEGREES OF SOCIAL RISK, WHO RECEIVED EITHER LCPT OR IR TACROLIMUS | $120,293 | 0 | 1 |
| Prospective Pilot Feasibility Study Comparing Envarsus Onceaday to Tacrolimus Twiceaday Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients | $119,933 | 0 | 3 |
| Early Use of Longacting Tacrolimus in Lung Transplant Recipients | $102,729 | 0 | 1 |
| A Prospective, Randomized, Single-center, Pilot Study of Envarsus XR to Examine Safety, Medication Adherence, and Patient Reported Outcomes in Adolescent Renal Transplant Recipients | $88,949 | 0 | 1 |
| An Evaluation of Converting Elderly Kidney Transplant Recipients from Tacrolimus to Envarsus to Limit Neurological Adverse Events and Improve Quality of Life | $87,500 | 0 | 4 |
| A 12 Month Singlecenter Open Label Randomized Comparative Study to Evaluate Envarsus XL Steroidfree Rabbit Antithymocyte Globulin Induction on Renal Function and Healthrelated Quality of Life Following Liver Transplantation | $84,420 | 0 | 4 |
| Veloxis de Novo Kidney Transplant ECSWD | $82,096 | 0 | 1 |
| VELOXIS DE NOVO KIDNEY TRANSPLANT ECSWD | $82,096 | 0 | 1 |
| Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus EVOKE RT | $80,978 | 0 | 3 |
| Role for Envarsus in Renal Transplant Recipients | $79,200 | 0 | 4 |
| Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (SIMPLE) | $75,292 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Joseph Melancon, M.d, M.D | Transplant Surgery | Washington, DC | $290,442 | $0 |
| Dr. Jason Wellen, Md, MD | Transplant Surgery | Saint Louis, MO | $203,224 | $0 |
| Dr. Tarek Alhamad, Md, MD | Nephrology | Saint Louis, MO | $108,428 | $0 |
| Deepak Mital, M.d, M.D | Transplant Surgery | Oak Lawn, IL | $100,601 | $0 |
| Dr. Rupinder Sodhi, Md, MD | Hospitalist | Maywood, IL | $76,814 | $0 |
| Dr. Suphamai Bunnapradist, M.d, M.D | Nephrology | Los Angeles, CA | $76,234 | $0 |
| Dr. Michael Goldstein, Md, MD | Transplant Surgery | Hackensack, NJ | $69,822 | $0 |
| Prince Anand, M.d, M.D | Internal Medicine | Danville, PA | $68,302 | $0 |
| Alexander Wiseman, Md, MD | Nephrology | Denver, CO | $67,855 | $0 |
| Dr. Tariq Shah, M.d, M.D | Nephrology | Los Angeles, CA | $67,293 | $0 |
| Jay Graham, M.d, M.D | Surgery | Newark, NJ | $62,903 | $0 |
| Dr. Yasir Qazi, M.d, M.D | Nephrology | Orange, CA | $55,671 | $0 |
| Dr. Christina Klein, Md, MD | Nephrology | Atlanta, GA | $53,713 | $0 |
| Steven Potter, M.d, M.D | Transplant Surgery | Washington, DC | $53,192 | $0 |
| Dr. Neeraj Singh, M.d, M.D | Nephrology | New Brunswick, NJ | $53,114 | $0 |
| Dr. Sridhar Allam, M.d., M.p.h, M.D., M.P.H | Nephrology | Mcallen, TX | $52,875 | $0 |
| Amit Govil, M.d, M.D | Internal Medicine | Cincinnati, OH | $48,435 | $0 |
| Reginald Gohh, Md, MD | Nephrology | Riverside, RI | $47,784 | $0 |
| Dr. Arman Faravardeh, M.d., F.a.c.p, M.D., F.A.C.P | Nephrology | San Diego, CA | $47,537 | $0 |
| Dr. Rafael Villicana, Md, MD | Nephrology | Loma Linda, CA | $43,559 | $0 |
| Aneesha Shetty, M.d., M.p.h, M.D., M.P.H | Internal Medicine | Tucson, AZ | $39,874 | $0 |
| Dr. Daniel Brennan, Md, MD | Nephrology | Baltimore, MD | $39,340 | $0 |
| Fuad Shihab, Md, MD | Nephrology | Salt Lake City, UT | $39,069 | $0 |
| Robert Redfield, Md, MD | Surgery | Orange, CA | $37,132 | $0 |
| Dr. Michael Marvin, Md, MD | Surgery | Danville, PA | $35,838 | $0 |
Ad
Top Products
- Envarsus $5.1M
- Envarsus XR $1.5M
Associated Products (6)
- Envarsus $5.1M
- Envarsus XR $1.5M
- ENVARSUS $1.4M
- VEL-101 $784,213
- Envarsus XR (SP) $477,456
- ART-123 $366,920
Payment Categories
- Food & Beverage $369,039
- Consulting $1.3M
- Travel & Lodging $612,433
- Research $9.0M
About Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals, Inc. has made $12.2M in payments to 2,448 healthcare providers, recorded across 9,583 transactions in the CMS Open Payments database. In 2024, the company paid $1.5M. The top product by payment volume is Envarsus ($5.1M).
Payments were distributed across 81 medical specialties. The top specialty by payment amount is Nephrology ($1.1M to 726 doctors).
Payment categories include: Food & Beverage ($369,039), Consulting ($1.3M), Research ($9.0M), Travel & Lodging ($612,433).
Veloxis Pharmaceuticals, Inc. is associated with 6 products in the CMS Open Payments database, including Envarsus, Envarsus XR, and ENVARSUS.